Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)

Yuan Hung Kuo; Sheng Nan Lu; Yen Yang Chen; Kwong Ming Kee; Yi Hao Yen; Chao Hung Hung; Tsung Hui Hu; Chien Hung Chen; Jing Houng Wang

doi:10.3389/fonc.2021.823960

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)

Yuan Hung Kuo, Sheng Nan Lu, Yen Yang Chen, Kwong Ming Kee, Yi Hao Yen, Chao Hung Hung, Tsung Hui Hu, Chien Hung Chen, Jing Houng Wang^*

^*Corresponding author for this work

School of Medicine

Chang Gung University

Research output: Contribution to journal › Comment/debate

10 Scopus citations

Abstract

In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”. A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Original language	English
Article number	823960
Journal	Frontiers in Oncology
Volume	11
DOIs	https://doi.org/10.3389/fonc.2021.823960
State	Published - 14 12 2021

Bibliographical note

Publisher Copyright:
© 2021 Kuo, Lu, Chen, Kee, Yen, Hung, Hu, Chen and Wang.

Keywords

hepatocellular carcinoma
lenvatinib
progression-free survival
propensity score (PS) matching (PSM)
sorafenib

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fonc.2021.823960

Fingerprint

Dive into the research topics of 'Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)'. Together they form a unique fingerprint.

Cite this

Kuo, Y. H., Lu, S. N., Chen, Y. Y., Kee, K. M., Yen, Y. H., Hung, C. H., Hu, T. H., Chen, C. H., & Wang, J. H. (2021). Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767). Frontiers in Oncology, 11, Article 823960. https://doi.org/10.3389/fonc.2021.823960

@article{5cd319dbb8074c5e9a43b05d014ca867,

title = "Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)",

abstract = "In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”. A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.",

keywords = "hepatocellular carcinoma, lenvatinib, progression-free survival, propensity score (PS) matching (PSM), sorafenib",

author = "Kuo, {Yuan Hung} and Lu, {Sheng Nan} and Chen, {Yen Yang} and Kee, {Kwong Ming} and Yen, {Yi Hao} and Hung, {Chao Hung} and Hu, {Tsung Hui} and Chen, {Chien Hung} and Wang, {Jing Houng}",

note = "Publisher Copyright: {\textcopyright} 2021 Kuo, Lu, Chen, Kee, Yen, Hung, Hu, Chen and Wang.",

year = "2021",

month = dec,

day = "14",

doi = "10.3389/fonc.2021.823960",

language = "英语",

volume = "11",

journal = "Frontiers in Oncology",

issn = "2234-943X",

}

Kuo, YH, Lu, SN, Chen, YY, Kee, KM, Yen, YH, Hung, CH, Hu, TH, Chen, CH & Wang, JH 2021, 'Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)', Frontiers in Oncology, vol. 11, 823960. https://doi.org/10.3389/fonc.2021.823960

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767). / Kuo, Yuan Hung; Lu, Sheng Nan; Chen, Yen Yang et al.
In: Frontiers in Oncology, Vol. 11, 823960, 14.12.2021.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Corrigendum

T2 - Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)

AU - Kuo, Yuan Hung

AU - Lu, Sheng Nan

AU - Chen, Yen Yang

AU - Kee, Kwong Ming

AU - Yen, Yi Hao

AU - Hung, Chao Hung

AU - Hu, Tsung Hui

AU - Chen, Chien Hung

AU - Wang, Jing Houng

PY - 2021/12/14

Y1 - 2021/12/14

N2 - In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”. A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

AB - In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”. A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

KW - hepatocellular carcinoma

KW - lenvatinib

KW - progression-free survival

KW - propensity score (PS) matching (PSM)

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85121965719&partnerID=8YFLogxK

U2 - 10.3389/fonc.2021.823960

DO - 10.3389/fonc.2021.823960

M3 - 评论/辩论

AN - SCOPUS:85121965719

SN - 2234-943X

VL - 11

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 823960

ER -

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis (Front. Oncol., (2021), 11, (737767), 10.3389/fonc.2021.737767)

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this